Income Tax Expense (Benefit) in USD of Cytek Biosciences, Inc. from Q2 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Cytek Biosciences, Inc. quarterly/annual Income Tax Expense (Benefit) history and change rate from Q2 2020 to Q3 2025.
  • Cytek Biosciences, Inc. Income Tax Expense (Benefit) for the quarter ending 30 Sep 2025 was -$2,291,000.000, a 192% decline year-over-year.
  • Cytek Biosciences, Inc. Income Tax Expense (Benefit) for the twelve months ending 30 Sep 2025 was -$2,667,000.000, a 52.2% decline year-over-year.
  • Cytek Biosciences, Inc. annual Income Tax Expense (Benefit) for 2024 was $320,000.000.
  • Cytek Biosciences, Inc. annual Income Tax Expense (Benefit) for 2023 was -$3,561,000.000, a 191% decline from 2022.
  • Cytek Biosciences, Inc. annual Income Tax Expense (Benefit) for 2022 was -$1,224,000.000, a 142% decline from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)

Cytek Biosciences, Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$2,667,000 -$2,291,000 -$1,507,000 -1.9% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025
Q2 2025 -$1,160,000 -$1,192,000 -$4,440,000 -1.4% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025
Q1 2025 $3,280,000 $136,000 +$2,960,000 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025
Q4 2024 $320,000 $680,000 +$2,072,000 01 Oct 2024 31 Dec 2024 10-K 28 Feb 2025
Q3 2024 -$1,752,000 -$784,000 -$3,055,000 -1.3% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025
Q2 2024 $1,303,000 $3,248,000 +$5,455,000 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025
Q1 2024 -$4,152,000 -$2,824,000 -$591,000 -26.5% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025
Q4 2023 -$3,561,000 -$1,392,000 -$1,788,000 -4.5% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2025
Q3 2023 -$1,773,000 $2,271,000 +$2,047,000 +9.1% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 -$3,820,000 -$2,207,000 -$1,508,000 -2.2% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024
Q1 2023 -$2,312,000 -$2,233,000 -$1,088,000 -95% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024
Q4 2022 -$1,224,000 $396,000 -$1,213,000 -75.4% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2025
Q3 2022 -$11,000 $224,000 -$431,000 -65.8% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 $420,000 -$699,000 -$1,296,000 -2.2% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023
Q1 2022 $1,716,000 -$1,145,000 -$1,195,000 -23.9% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023
Q4 2021 $2,911,000 $1,609,000 01 Oct 2021 31 Dec 2021 10-K 13 Mar 2024
Q3 2021 $655,000 +$298,000 +83.5% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022
Q2 2021 $597,000 +$8,516,000 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022
Q1 2021 $50,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022
Q3 2020 $357,000 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$7,919,000 01 Apr 2020 30 Jun 2020 10-Q 03 Sep 2021

Cytek Biosciences, Inc. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $320,000 +$3,881,000 01 Jan 2024 31 Dec 2024 10-K 28 Feb 2025
2023 -$3,561,000 -$2,337,000 -1.9% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2025
2022 -$1,224,000 -$4,135,000 -1.4% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2025
2021 $2,911,000 +$7,892,000 01 Jan 2021 31 Dec 2021 10-K 13 Mar 2024
2020 -$4,981,000 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.